Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kawakami, Atsushi
ARRIA, NCT06611696: Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis	Not yet recruiting	4	160	Japan	Avacopan, prednisolone and rituximab, Prednisolone and rituximab	Chiba University, Kissei Pharmaceutical Co., Ltd., International University of Health and Welfare	ANCA Associated Vasculitis (AAV)	03/27	09/28
TRANSFORM, NCT05090410: Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Recruiting	3	400	Japan	filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly	Atsushi Kawakami, Gilead Sciences	Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound, Biomarker	02/23	12/23
DOPPLER, NCT05121298: Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	Recruiting	3	155	Japan	upadacitinib 15mg/day	Atsushi Kawakami, AbbVie GK.	Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound, Biomarker	11/23	09/24
NCT05814159: A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)	Active, not recruiting	3	15	Japan	Anakinra, Kineret, Placebo	Swedish Orphan Biovitrum, CMIC Co, Ltd. Japan	Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset	12/25	06/26
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Active, not recruiting	2/3	301	Europe, Japan, US, RoW	HZN-825 BID, Placebo, HZN-825 QD	Amgen, Horizon Therapeutics USA, Inc	Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic	09/25	09/25
NCT05411016: A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus	Recruiting	1	157	Japan, RoW	Placebo, KK4277	Kyowa Kirin Co., Ltd.	Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)	12/24	12/25
Shimizu, Masaki
NCT05814159: A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)	Active, not recruiting	3	15	Japan	Anakinra, Kineret, Placebo	Swedish Orphan Biovitrum, CMIC Co, Ltd. Japan	Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset	12/25	06/26
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)	Recruiting	3	58	Europe, Japan, RoW	Baricitinib, LY3009104, Tocilizumab	Eli Lilly and Company	Systemic Juvenile Idiopathic Arthritis	04/26	05/26
JUVE-X, NCT03773965 / 2017-004471-31: A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis	Recruiting	3	190	Europe, Japan, RoW	Baricitinib, LY3009104	Eli Lilly and Company	Juvenile Idiopathic Arthritis	07/31	07/31
Kawamoto, Ami
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27